Tru is a technology company.
Tru has raised $11.0M across 2 funding rounds.
Tru has raised $11.0M in total across 2 funding rounds.
Tru has raised $11.0M in total across 2 funding rounds.
Tru's investors include Big Idea Ventures, Btomorrow Ventures, Rajan Anandan, SOSV.
# High-Level Overview
The search results reveal multiple companies operating under "Tru" or similar branding, making it necessary to clarify which entity you're asking about. The most prominent is TruTechnologies, a clinical trial oversight company founded in 2018[1]. TruTechnologies builds TruLab, a real-time clinical trial management platform that addresses a critical problem in pharmaceutical research: approximately 20% of clinical trial samples are rendered unusable due to preventable errors[1]. The company serves biopharma organizations, contract research organizations (CROs), and central laboratories by providing software that monitors protocol compliance, eliminates duplicative tasks, and enables on-the-go support for clinical trial sites globally[1].
The company's mission centers on streamlining clinical trials through real-time oversight of biological sample management and broader protocol compliance monitoring[1]. TruTechnologies is headquartered in Research Triangle Park, North Carolina, positioning it within the biotech corridor[1].
# Origin Story
TruTechnologies was founded in 2018 by Richard Graham, PhD (Chairman & Co-founder) and Scott Ogle (CEO & Co-founder), both biopharma and technology professionals[1]. The company emerged from identifying a fundamental operational problem: the pharmaceutical industry lacked effective real-time visibility into clinical trial sample integrity and protocol adherence[1]. What began as a focused solution for biological sample tracking evolved into a broader platform addressing protocol compliance challenges across clinical research operations[1]. This evolution—from sample management to comprehensive trial oversight—reflects the company's learning that tracking samples ultimately serves as a proxy for monitoring real-time protocol compliance[1].
# Core Differentiators
# Role in the Broader Tech Landscape
TruTechnologies operates within the clinical trial digitalization trend, where pharmaceutical companies increasingly seek software solutions to improve data quality, accelerate timelines, and reduce costs. The company addresses a specific but critical gap: while clinical trial management systems exist, few focus on real-time protocol compliance and sample integrity monitoring at the operational level. As regulatory scrutiny of clinical trial data intensifies and sponsors face pressure to reduce trial timelines and costs, solutions that prevent data loss and protocol deviations become strategically valuable. TruTechnologies' expansion of its global footprint and partnerships with leading CROs and central labs suggests the market is receptive to this approach[1].
# Quick Take & Future Outlook
TruTechnologies is well-positioned within the growing clinical trial technology market, where digitalization and real-time oversight are becoming competitive necessities rather than differentiators. The company's rebranding from a sample-tracking focus to broader protocol compliance reflects market maturation and expanding use cases. Future growth will likely depend on deepening integrations with major clinical trial management platforms, expanding into emerging markets, and demonstrating measurable improvements in trial timelines and data quality. As the pharmaceutical industry continues investing in operational efficiency, TruTechnologies' ability to quantify and prevent the costly problem of sample failure positions it as a valuable infrastructure layer in modern clinical research.
Tru has raised $11.0M across 2 funding rounds. Most recently, it raised $7.0M Series A in February 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2023 | $7.0M Series A | Big Idea Ventures, Btomorrow Ventures, Rajan Anandan, SOSV | |
| Oct 1, 2021 | $4.0M Seed | Btomorrow Ventures, SOSV |